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Abstract
Background: To evaluate effectiveness outcomes in a real-world setting in patients with schizophrenia initiating
risperidone long-acting therapy (RLAT).
Methods: This was a 24-month, multicenter, prospective, longitudinal, observational study in patients with
schizophrenia who were initiated on RLAT. Physicians could change treatment during the study as clinically
warranted. Data were collected at baseline and subsequently every 3 months up to 24 months. Effectiveness
outcomes included changes in illness severity as measured by Clinical Global Impression-Severity (CGI-S) scale;
functional scores as measured by Personal and Social Performance (PSP) scale, Global Assessment of Functioning
(GAF), and Strauss-Carpenter Levels of Functioning (LOF); and health status (Medical Outcomes Survey Short Form-
36 [SF-36]). Life-table methodology was used to estimate the cumulative probability of relapse over time. Adverse
events were evaluated for safety.
Results: 532 patients were enrolled in the study; 209 (39.3%) completed the 24-month study and 305 (57.3%) had
at least 12 months of follow-up data. The mean (SD) age of patients was 42.3 (12.8) years. Most patients were male
(66.4%) and either Caucasian (60.3%) or African American (23.7%). All changes in CGI-S from baseline at each
subsequent 3-month follow-up visit were statistically significant (p < .0001), indicating improvement in disease
severity. Improvements were also noted for the PSP, GAF, and total LOF, indicating improvement in daily
functioning and health outcome.
Conclusions: Patients with schizophrenia who were initiated on RLAT demonstrated improvements in measures of
effectiveness within 3 months, which persisted over 24 months.
Trial Registration: ClinicalTrials.gov: NCT00246194
Background
Schizophrenia is a chronic debilitating mental illness
with a lifetime prevalence of 1% [1], characterized by
perturbations of cognition and behavior and by abnor-
mal or limited display of emotion. Because of the sever-
ity of symptoms and the long-term, chronic pattern of
schizophrenia, patients often have significant disability
with serious physical, social, and economic conse-
quences [2,3]. Major treatment goals are to maintain
symptom relief, decrease relapses, increase functioning,
and improve quality of life.
Long-term antipsychotic therapy is the cornerstone of
schizophrenia management [4]. First-generation or con-
ventional oral antipsychotic agents, such as fluphenazine
and haloperidol, have been used for decades to treat
patients with schizophrenia and are effective in reducing
many symptoms of the disease. However, adverse events
(AEs) associated with these drugs, including the risk of
extrapyramidal symptoms (e.g., dystonias, parkinsonism,
and akathisia) and tardive dyskinesia at therapeutic
doses limit their use in some patients. Long-acting
injectable antipsychotics (e.g., fluphenazine decanoate,
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ment and improve adherence. The pharmacokinetic pro-
file of these agents showed reduced differences in peak
and trough plasma drug levels, which allowed for more
reliable drug delivery [5]. Meta-analysis of injectable ver-
sus oral therapy showed that relapse rates were signifi-
cantly lower with injectable therapy [6-8].
Several of the second-generation or “atypical” agents,
including risperidone, have been shown to be more
effective than conventional antipsychotics [9] and have
an improved safety profile with lower risk of extrapyra-
midal AEs and tardive dyskinesia [10-12], although the
incidence of extrapyramidal AEs may vary among the
atypical antipsychotics [13]. Atypical long-acting antipsy-
chotic therapy, a relatively new treatment modality in
many systems of care, is an important treatment option
for many patients with chronic disease. Risperidone
long-acting therapy (RLAT) is an atypical antipsychotic
approved for the treatment of schizophrenia [14]. Short-
and long-term studies have established the efficacy and
tolerability of RLAT in patients with schizophrenia
[4,15,16]. In addition, RLAT treatment is associated
with low relapse and rehospitalization rates [17-22],
improved treatment adherence [23], and health-related
quality of life [24].
Patients with schizophrenia often have poor adherence
to medication, with up to 50% of patients either partially
adherent or nonadherent to medication within 1 year
after discharge [25]. Nonadherence is a contributing fac-
tor for patients relapsing [26,27] and may become more
important over time [7]. Use of antipsychotic medication
reduces the rate of relapse in schizophrenic psychoses
from 75% to 20% [28]. Strategies that improve adher-
ence to antipsychotic therapy, such as simplification of
medication regimens, monotherapy, and use of long-act-
ing injectable therapy, may lead to improved outcomes
[4,29]. Long-acting injectable therapies are convenient (i.
e., patients take one fewer medication every day) and,
because the injections must be administered by a health
care provider, the clinical team is immediately alerted
when a patient is nonadherent [20,29].
Observational studies that collect data from naturalis-
tic clinical practice settings complement data collected
from randomized controlled trials. By collecting obser-
vational data, the clinical effectiveness of RLAT on
important outcomes such as health-related quality of
life, disease severity, patient functionality, and tolerabil-
ity can be further understood in the context of the
wider spectrum of care. The Schizophrenia Outcomes-
Utilization, Relapse, and Clinical Evaluation (SOURCE)
study was a large-scale, prospective, observational study
designed to observe effectiveness outcomes and toler-
ability of RLAT in real-world practice by following
patients with schizophrenia initiated on RLAT for 2
years. Results of the effectiveness outcomes measures
from the SOURCE study are presented herein.
Methods
Study design
This was a 24-month, multicenter, prospective, longitu-
dinal, observational study (NCT00246194). A central
institutional review board (IRB; Quorum Review Inc.,
Seattle, WA) was used to review and approve the final
study protocol for all sites that participated in the study
with the exception of 9 sites that required local IRB
approval. This study was conducted in accordance with
the ethical principles established in the Declaration of
Helsinki and that are consistent with Good Clinical
Practice and applicable regulatory requirements. All sub-
jects provided written consent.
Patients eligible for enrollment were those aged 18
years and older who required treatment initiation on
RLAT, had a physician-based diagnosis of schizophrenia
according to the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition, and provided written
informed consent. Patients who were at imminent risk
of injury to themselves or others or of causing signifi-
cant damage to property, who had a known hypersensi-
tivity to RLAT or any of its components, or who had
been treated with investigational agents within the pre-
vious 30 days were not eligible for enrollment. Women
of childbearing potential who were not using an ade-
quate method of contraception and women who were
pregnant or breast-feeding were also not eligible for
participation.
Patients were enrolled from 67 community mental
health centers and Veterans Administration Hospitals in
the United States (US) from September 2004 until Janu-
ary 2006, with follow-up visits through October 2007.
The RLAT starting dose that was recommended to phy-
sicians was 25 mg administered every 2 weeks by deep
intramuscular gluteal injection. Physicians were per-
mitted to provide a higher RLAT dose if they deemed it
necessary for their patients. After enrollment, however,
specific clinical interventions were not mandated other
than the initiation of RLAT at the beginning of the
study; therefore, treatments for schizophrenia could be
stopped, started, or changed as deemed appropriate by
the patient’s physician. Concomitant medications could
be added to treatment regimens at the discretion of the
investigator.
Assessments
Demographic and clinical characteristics were collected
at baseline and included age, gender, ethnicity, diagno-
sis, duration of illness, and employment status. Antipsy-
chotic medication history during at least the past 12
months and current antipsychotic medications were
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were performed every 3 months for 2 years. Disease
severity at the time of evaluation was assessed by the
Clinical Global Impression-Severity (CGI-S) [30] scale,
which is a subjective measure of disease severity made
by the physician on a 7-point scale ranging from 1 (nor-
mal, not at all ill) to 7 (most severely ill).
Functionality was assessed by the Personal and Social
Performance (PSP) scale [31], Global Assessment of
Functioning (GAF) [32], and Strauss-Carpenter Levels of
Functioning (LOF) [33]. The PSP rates the patient’s
level of functioning during the past month in four areas:
socially useful activities, personal and social relation-
ships, self-care, and disturbing and aggressive behaviors.
Physicians assign a score that ranges from 1 (lack of
autonomy in basic functioning) to 100 (excellent func-
tioning in all four areas). The GAF is a single-item rat-
ing of the patient’s psychologic, social, and occupational
functioning on a hypothetical continuum of mental
health. Physicians rate the lowest level of function in the
last week, with scores ranging from 1 (persistent danger)
to 100 (superior functioning). The LOF evaluates func-
tionality in the last month in four areas: symptoms,
social contacts, work, and function. The physician rates
t h en i n ei t e m so ft h eL O Fo nas c a l eo f0( w o r s tf u n c -
tioning) to 4 (best functioning), with a possible maxi-
mum score of 36.
Health status was assessed with the Medical Out-
comes Survey Short Form-36 (SF-36) [34], a widely used
patient-reported outcomes instrument. The survey
includes 36 items and evaluates health status in the past
4 weeks, in eight different areas, that can be broadly
summarized as physical health (physical functioning,
role-physical, body pain, general health) and mental
health (vitality, social functioning, role-emotional, men-
tal health). From these domains, physical and mental
health component summary measures were also
obtained. In addition, AEs and serious adverse events
(SAEs) were collected during the study.
Statistical analysis
To ensure an adequate sample size, the number of
patients needed to detect meaningful changes in some
of the outcome measures was estimated. A 5-point
change on an individual SF-36 domain is considered
clinically and socially relevant [34]. To detect a 5-point
change on the most variable individual SF-36 domain
score (role-physical), with 80% power and 0.05 tolerance
of type 1 error, 293 evaluable patients were required,
based on a two-sided paired t test, assuming within-sub-
ject test-retest correlation of 0.60 and standard deviation
(SD) of 34 (data for the US normal subjects). This sam-
ple size also provided approximately 80% power for
detection of 0.165 standardized change (effect size) in
the average number of hospitalizations per year. In
terms of the precision of event rate estimation (e.g.,
relapse rate), 293 patients would provide a rate estimate
with a standard error of 3%. Assuming that approxi-
mately 50% of patients would drop out within 1 year
[35,36], enrollment of 600 patients was planned.
Analysis included evaluation of baseline demographics,
clinical characteristics, and functional scores. Categorical
variables were summarized using frequencies and per-
centages. Continuous measures were summarized with
mean, standard deviation, minimum, maximum, and
median.
Clinical effectiveness data were analyzed in patients
who had a non-missing baseline and at least one postba-
seline assessment for a given effectiveness measurement
and used mixed-model methodology with baseline value
as a covariate, a fixed effect for time, and a random
effect for center. An unstructured covariance matrix was
used to model within-subject correlation. Statistical ana-
lysis software (SAS, version 9.1) was used for all ana-
lyses. All tests were two-tailed and conducted at the 5%
significance level. Because of the exploratory nature of
the study, no correction was made for multiplicity.
Relapse was defined as either a psychiatric hospitaliza-
tion or the occurrence of a psychiatric event (defined as
deliberate self-injury, suicidal or homicidal ideation that
was clinically significant as determined by the investigator,
or violent behavior resulting in clinically significant injury
to another person or property damage). Life-table metho-
dology was used to estimate the cumulative probability of
relapse and the corresponding 95% confidence interval
(CI) at each 3-month postbaseline time interval. The con-
ditional probability of relapse for each follow-up time
interval (probability of having a relapse in the current time
interval for patients who were relapse free) was also calcu-
lated. Relapse time was censored at the last time interval
of known status if the patient had no relapse by the end of
the follow-up period, the patient withdrew from the study,
or the patient was lost to follow-up.
An exploratory analysis was conducted to evaluate the
impact of RLAT discontinuation among patients who
had all nine visits and at least one RLAT injection
record in the injection log. Effectiveness measures were
compared with those receiving or not receiving RLAT.
Each visit was identified as a visit during which the
patient either received RLAT or did not receive RLAT.
Patients were counted as having received RLAT at a
visit if they had at least one record for RLAT in the
injection log within 28 days prior to the visit. Because
RLAT steady-state plasma concentrations are main-
tained at a minimum of 4 weeks after the last injection
[14], the 28-day interval was chosen by the investigators
to establish a time frame in which RLAT may not be
able to provide adequate efficacy. Effectiveness was
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lected at each visit. A mixed-model analysis of covar-
iance was used to analyze the ranked change from
baseline for each effectiveness score. The models
included baseline value for the effectiveness measure,
visit, an indicator variable for whether the patient was
or was not receiving RLAT, and an interaction term
between the visit and the RLAT indicator variable. The
ap r i o r ihypothesis focused on the differences between
patients receiving or not receiving RLAT at each visit.
AEs and SAEs were summarized descriptively.
Results
The study enrolled 532 patients; 305 (57.3%) had 12
months and 209 (39.3%) patients had 24 months of fol-
low-up data and completed all 9 visits. Disposition of
patients is summarized in Table 1.
The mean (SD) age was 42.3 (12.8) years, and 66.4% of
patients were male. Most patients were Caucasian
(60.3%) or African American (23.7%). Mean (SD) length
of diagnosis was 17.9 (12.3) years. Baseline characteris-
tics are summarized in Table 2. Of the 532 patients, 186
(36.0%) were recorded by their investigators to have
received at least one antipsychotic other than RLAT
after the baseline visit.
The most common reasons for initiating RLAT were
insufficient response to previous therapy (53.8%) and
lack of adherence to previous therapy (48.1%). RLAT
was initiated at a dose of 25 mg in 75% of patients and
at either 37.5 mg (13%) or 50 mg (11%) in the remain-
ing patients.
Health status
The mean (standard error [SE]) mental health compo-
nent summary scores from the SF-36 was 38.0 (0.8) at
baseline, 42.4 (0.9) at 12 months, and 44.5 (1.0) at the
final visit. Mean scores at all postbaseline visits were sta-
tistically significantly greater than baseline (p < .0001).
For the individual mental health domains of vitality,
social functioning, role-emotional, and mental health, all
postbaseline least squares (LS) means increased signifi-
cantly (p < .005) from baseline. No statistically signifi-
cant differences from baseline were observed in the
physical health component summary score.
Effectiveness outcomes
The mean CGI-S scores at baseline (unadjusted) and
each subsequent 3-month follow-up visit (LS means) are
shown in Figure 1. All differences from baseline were
statistically significant (p < .0001). The CGI-S score at
baseline was 4.5 (marked-to-moderate illness severity)
and decreased to 3.5 (moderate-to-mild illness severity)
at 24 months.
The mean PSP scores at baseline (unadjusted) and
each subsequent 3-month follow-up visit (LS means) are
shown in Figure 2. All differences from baseline were
statistically significant (p < .0001). The mean PSP score
at baseline was 48.3 and increased to 61.0 at 24 months,
indicating improvement after the initiation of RLAT.
The mean GAF scores at baseline (unadjusted) and
each subsequent 3-month follow-up visit (LS means) are
shown in Figure 3. All differences from baseline were
statistically significant (p < .0001). The mean GAF score
at baseline was 47.3 and increased to 60.5 at 24 months,
indicating an overall significant improvement in patient
functioning from serious to occasional impairment after
initiation of treatment with RLAT.
The total LOF scores at baseline (unadjusted) and
each subsequent 3-month follow-up visit (LS means) are
shown in Figure 4. All differences from baseline were
Table 1 Patient disposition
n (%)
Total patients enrolled 532
Patients with data at 12 months 305 (57.3)
Patients with data at 24 months 209 (39.3)
Discontinued 237 (44.5)
Reason for discontinuation
Lost to follow-up 73 (13.7)
Other 65 (12.2)
Withdrawal of consent 57 (10.7)
Patient nonadherence 21 (3.9)
Adverse event 7 (1.3)
Insufficient response 6 (1.1)
Death 5 (0.9)
Patient ineligible to continue trial 2 (0.4)
Missing 1 (0.2)
Not reported (no notification of discontinuation/no submission of 24-month data) 86 (16.2)
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scale score at baseline was 15.5 (of a maximum 36
points) and increased to 19.9 at 24 months, indicating
improvement in functionality after initiation on treat-
ment with RLAT.
Subgroup analysis
An analysis was conducted on the effectiveness mea-
sures of CGI-S and GAF in patients who remained in
the study for 24 months (n = 209 and n = 208, respec-
tively). Mean CGI-S and GAF scores over time were
evaluated, and the results on these measures were simi-
lar to what was observed for the entire sample, with sig-
nificant improvement seen at the first (3-month)
assessment, which persisted throughout the study.
Relapse
Half of the observed relapses occurred during the first 3
months of the study. The cumulative probability of
relapse was 10.6% (95% CI: 8.2% to 13.6%) by the end of
the first 3 months of the study and 28.5% (95% CI:
24.0% to 33.6%) by 24 months. Figure 5 shows the con-
ditional probability of relapse over time by visit. The
conditional probability of relapse decreased during the
24-month follow-up period (ranged from 1.8% to 4.9%).
Exposure and discontinuation analyses
Of the 209 patients who had 24 months of data and
attended all 9 visits, 202 patients had at least one docu-
mented RLAT injection recorded in the injection log
and were included in the exposure and discontinuation
analysis. RLAT status could not be determined for the
remaining 7 patients. Table 3 presents the number and
percentage of patients who received RLAT injection at
each visit. At the 3-month follow-up visit, 90.1% of
patients were treated with RLAT, and at the 24-month
follow-up visit, 77.2% were treated with RLAT.
Patients who continued to receive RLAT scored signif-
icantly better on measures of effectiveness (CGI-S, GAF,
and PSP) than did patients who had discontinued
RLAT. Patients receiving RLAT averaged approximately
a 0.4-point greater decrease on the CGI-S, indicating
improvements in illness severity, and approximately a 5-
point greater improvement in functionality compared
with patients not receiving RLAT (Figures 6, 7, 8). The
tests for whether patients were receiving RLAT and the
v i s i tv a r i a b l ew e r es i g n i f i c a n ta tp < .0001 in all models.
The interaction between the visit variable and the RLAT
variable was not significant in any of the models.
Adverse events
Of the 532 enrolled patients, 251 (47.2%) experienced at
least one AE, and 144 (27.1%) experienced at least one
SAE over the 24-month follow-up period. AEs reported
in more than ≥5% of patients were psychotic disorder
(9.4%), anxiety (7.7%), depression (7.5%), suicide idea-
tion (6.0%), insomnia (5.6%), and schizophrenia (4.5%).
Five patients died during the study; three due to cardiac
failure, one due to chronic obstructive pulmonary dis-
ease and cardiac failure, and one due to complications
Table 2 Baseline demographic and illness characteristics
(N = 532)
Age, y
a
Mean (SD) 42.3 (12.8)
Median (min, max) 43.2 (18, 80)
Gender, n (%)
Male 353 (66.4)
Female 179 (33.6)
Ethnicity, n (%)
Caucasian 321 (60.3)
African American 126 (23.7)
Hispanic 61 (11.5)
Mixed race 9 (1.7)
Other 8 (1.5)
Asian 7 (1.3)
Duration of schizophrenia, y
b
Mean (SD) 17.9 (12.3)
Median (min, max) 16.0 (0.0; 57.0)
Schizophrenia type, n (%)
Paranoid 359 (67.5)
Undifferentiated 98 (18.4)
Disorganized 59 (11.1)
Residual 10 (1.9)
Catatonic 4 (0.8)
Missing 2 (0.4)
Employment status, n (%)
c
Unemployed 218 (41.0)
Disabled/long-term sick leave 134 (25.2)
Part-time 19 (3.6)
Full-time 14 (2.6)
Student 5 (0.9)
Homemaker 4 (0.8)
Retired 3 (0.6)
Missing 176 (33.1)
Income, n (%)
<$20,000.00 239 (44.9)
$20,000 to $34,000 15 (2.8)
$35,000 to $49,999 4 (0.8)
$50,000 to $74,999 1 (0.2)
>$75,000.00 3 (0.6)
Patient refused 3 (0.6)
Patient unemployed 91 (17.1)
Missing 176 (33.1)
max, maximum; min, minimum; SD, standard deviation.
an = 528
bn = 518
cSum of percentages can be greater than 100 because patients can be in
more than one group.
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medication.
Discussion
The results of this observational study found that
patients with schizophrenia had reduced illness severity
(as measured by CGI-S) and improved clinician-rated
functioning (as measured by GAF, PSP, and LOF) after
3 months of treatment. These changes were maintained
for 24 months. Atypical antipsychotic agents have been
shown to have a positive impact on factors most asso-
ciated with quality of life (e.g., negative and affective
symptoms and drug tolerability); thus treatment with an
atypical agent such as RLAT may lead to improved
health status.
Because this was an open-label observational study with-
out a comparator group, its limitations require that these
data be interpreted cautiously and not be overly general-
ized. Initiation of RLAT at the beginning of the study was
the only clinical mandate, and treatments for schizophre-
nia including additional concomitant medications could
be stopped, started, or changed at the investigator’sd i s c r e -
tion. Therefore, patients could have been using additional
antipsychotics during the study, and the effectiveness
observed may have been derived from different medica-
tions other than RLAT. In the total population, 36% of
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additional antipsychotics other than RLAT. However,
since the accuracy of information depended on clinician
reports, patients other than those documented may have
been using additional antipsychotics.
RLAT and other long-acting injectables are thought to
improve treatment adherence [23], hence, the high drop-
out rate was of concern as it may have affected the results.
However, because this was an observational study, patients
were not obligated to participate in all 9 visits. Although
the sample size decreased by 60% over the course of the
current study, high dropout rates are common in observa-
tional studies with extended follow-ups.
To address these potential biases, an exploratory sub-
group analysis was conducted in patients who had 24
months of data and received RLAT within 28 days of
the study visit in order to evaluate a patient population
in which RLAT use was known. In this population,
patients receiving RLAT had greater improvements in
effectiveness measures than patients not receiving
RLAT. The results within this cohort were almost iden-
tical to those observed for the entire sample, which
increases the validity of these data.
Although the data from this study should be inter-
preted cautiously, the results compare favorably with
previously reported studies evaluating RLAT in
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assessment of their GAF score. *Changes from each visit compared with baseline (visit 1) were significant at p < .0001.
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reported data [25,37], a significant decrease of 1.3
points in mean CGI-S score from baseline (4.5 points
indicative of marked-to-moderate illness severity) to 24
months (3.2 points indicative of moderate-to-mild ill-
ness severity) was noted. Significant improvements of
up to 22% were also observed in global functioning,
corresponding to a change from serious to moderate
disability. Furthermore, in this study, the 2-year esti-
mated cumulative relapse rate was 28.5%, which com-
pares favorably with literature-reported relapse rates. A
1-year relapse rate of 18% and 2-year relapse rate of
23% were observed in a study of first-episode schizo-
phrenic patients receiving RLAT compared with 50%
and 75%, respectively, for patients receiving oral
risperidone [38]. In a post hoc comparison of respon-
der patients in South Africa, relapse rates at 24
months were 9.3% for patients receiving RLAT and
42.1% for those receiving oral risperidone or haloperi-
dol [33]. Stable schizophrenic patients who were ran-
d o m i z e dt ot w of i x e dd o s e so fR L A Th a d1 - y e a r
incidence of relapse of 15% and 22% [17].
Improvement in health status, as assessed by the SF-
36 mental health domains and summary measure, was
also observed at 3 months and maintained for 24
months. Significant and sustained improvements in
negative symptoms and positive changes in mental
health quality of life have been reported at 1 month and
up to 6 months after open-label treatment with RLAT
[39-42]. Improved health status with RLAT was also
observed by Nasrallah et al. in a double-blind study
comparing patients receiving RLAT with those receiving
a placebo [24].
The SOURCE study, to the best of our knowledge, is
the first 24-month observational study in the US to fol-
low these effectiveness measures in schizophrenic
patients initiated on RLAT. Additionally, the electronic
Schizophrenia Treatment Adherence Registry (eSTAR),
an ongoing multinational, observational registry study,
has been evaluating outcomes in patients with schizo-
phrenia. After 24 months of follow-up in eSTAR in
Spain, RLAT use was associated with increased efficacy
[23]. Additional eSTAR results on pooled data from six
and eight other countries participating in eSTAR
showed significant improvement in CGI-S and GAF
scores [43,44].
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Figure 5 Conditional probability of relapse by visit. P, probability.
Table 3 Patients who received or did not receive RLAT
who had 24 months of data and received RLAT within 28
days of the study visit
Visit Receiving RLAT Not Receiving RLAT
Baseline n % n %
202 100 0 0
3 months 182 90.1 20 9.9
6 months 182 90.1 20 9.9
9 months 173 85.6 29 14.4
12 months 167 82.7 35 17.3
15 months 164 81.2 38 18.8
18 months 163 80.7 39 19.3
21 months 160 79.2 42 20.8
24 months 156 77.2 46 22.8
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Although efficacy and safety data from randomized con-
trolled clinical trials are the mainstay of regulatory deci-
sion-making for drug marketing approval, interest in
well-designed postapproval observational and registry
studies has increased and the results from these studies
may have broader applicability [45]. Clinical manage-
ment of patients with schizophrenia is lifelong and
requires family, social, and therapeutic interventions,
including antipsychotic therapy, to stabilize and support
patients. In the SOURCE study, initiation and continua-
tion of RLAT may support the long-term effectiveness
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Figure 6 Least-squares (LS) mean Clinical Global Impression-Severity (CGI-S) change from baseline by visit and discontinuation status.
Patients included in this analysis were those who had 24 months of data and had all nine visits and at least one RLAT injection record in the
injection log. Model: CGI-S Change From Baseline = Baseline CGI-S Value + Visit + Stayed On/Dropped Off Maker + Visit*Drop Off Interaction
Term. p-values were generated from a model using ranks of CGI-S change from baseline as the dependent variable. *All values except visit 7
were significant at p < .05; for visit 7, p = .2081.
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Figure 7 Least-squares (LS) mean Personal and Social Performance (PSP) change from baseline by visit and discontinuation status.
Patients included in this analysis were those who had 24 months of data and had all nine visits and at least one RLAT injection record in the
injection log. Model: PSP Change From Baseline = Baseline PSP Value + Visit + Stayed On/Dropped Off Maker + Visit*Drop Off Interaction Term.
p-values were generated from a model using ranks of PSP change from baseline as the dependent variable. *All values except visit 3 were
significant at p < .05; for visit 3, p = .1309.
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Page 9 of 12goals by reducing disease severity and improving func-
tion and mental health-related quality of life.
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